Research programme: antibody therapeutics - Sutro Biopharma

Drug Profile

Research programme: antibody therapeutics - Sutro Biopharma

Alternative Names: anti CD 74 antibody drug conjugates - Sutro Biopharma; SP 7219; SP 7675; SP 7676; STRO 001

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator Sutro Biopharma
  • Class Antibodies; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Dec 2016 Sutro Biopharma announces intention to initiate IND-enabling studies of STRO 001 for B-cell haematologic malignancies
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 19 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top